Sangamo Biosciences (NASDAQ: SGMO) reported Q2 EPS of ($0.17), versus ($0.38) reported last year. Revenue for the quarter came in at $8.3 million, versus $3.7 million reported last year.

GUIDANCE:

Sangamo Biosciences sees FY2017 revenue of $30-40 million, versus the consensus of $31.2 million.

For earnings history and earnings-related data on Sangamo Biosciences (SGMO) click here.